Back to search

Article

Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomized, double-blind, non-inferiority trial

2020-08-21

Abstract excerpt

<h4>Background</h4> Yellow fever vaccine stocks have been insufficient to cover exceptional demands for outbreak response. Fractional dosing evidence is limited to the 17DD substrain vaccine. We assessed the immunogenicity and safety of one-fifth fractional dose compared to standard dose of each of the four WHO-prequalified yellow fever vaccines produced from three substrains. <h4>Methods</h4> We conducted a rando...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a3e83a91-bfd0-5b3a-9429-162c80993dce
DOI
10.1101/2020.08.18.20177527
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomized, double-blind, non-inferiority trialDOI 10.1101/2020.08.18.20177527
Safety and Immunogenicity of Fractional Doses of COVID-19 Vaccines among Nigerian Adults- A Randomised Non-Inferiority trialSemantic proximity
The 17D-204 and 17DD yellow fever vaccines: an overview of major similarities and subtle differencesSemantic proximity
A Triple-Blinded Randomized Control Trial to Evaluate the Safety and Immunogenicity of Fractional Doses of COVID-19 Vaccines (ChAd0x1, AD26.COV2.S, and BNT162B2) Among Nigeria Adults: The SIFCoVAN TrialSemantic proximity
The Yellow Fever Vaccine Journey: Milestones and Future DirectionsSemantic proximity
Evaluation of the safety and immunogenicity of fractional intradermal COVID-19 vaccines as a booster: A pilot studySemantic proximity
Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: an open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled studySemantic proximity
Antigen-specific T cell responses following single and co-administration of tick-borne encephalitis, Japanese encephalitis, and yellow fever virus vaccines: Results from an open-label, non-randomized clinical trial-cohortSemantic proximity
First-in-human, phase 1, randomized, observer-blind, controlled trial to assess the safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adultsSemantic proximity
Dose of approved COVID-19 vaccines is based on weak evidence: a review of early-phase, dose-finding trialsSemantic proximity
Immunogenicity, Safety, and Reactogenicity of a Half- Versus Full-Dose BNT162b2 (Pfizer-Biontech) Booster Following a Two-Dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac Priming Schedule in Mongolia: A Randomised, Controlled, Non-Inferiority TrialSemantic proximity
Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the CongoSemantic proximity
Characterising the benefits and risks of vaccines approved through accelerated pathwaysSemantic proximity
Select a neighboring publication to make it the new centre.